# Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia

> **NCT00003405** · PHASE2 · WITHDRAWN · sponsor: **Rush University Medical Center**

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** recombinant interferon alfa
- **DRUG:** amifostine trihydrate
- **DRUG:** bromodeoxyuridine
- **DRUG:** cytarabine
- **DRUG:** idarubicin
- **DRUG:** idoxuridine
- **DRUG:** isotretinoin
- **DRUG:** mitoxantrone hydrochloride

## Key facts

- **NCT ID:** NCT00003405
- **Lead sponsor:** Rush University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 1998-04
- **Primary completion:** 1999-04
- **Final completion:** 1999-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No enrollment
- **Last updated:** 2021-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003405, "Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00003405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*